Search

Memorial Sloan Kettering Cancer Center (MSKCC) today celebrated a new outpatient chemotherapy center, which is scheduled to open later this month, pending approval from the State Department of Health. The 7,745-square-foot facility, called the Brooklyn Infusion Center, will provide leading-edge chemotherapy services to current MSKCC patients who live in or near Brooklyn - which amounts to more than 15 percent of MSKCC's patients currently being treated in Manhattan.

… Monday, September 13, 2010 Memorial Sloan Kettering Cancer Center (MSKCC) today celebrated a new outpatient chemotherapy center, which is scheduled to open later this month, pending approval from the State Department of Health. The 7,745-square-foot facility, called the Brooklyn Infusion Center , will

Memorial Sloan Kettering Cancer Center (MSK) is proud to announce three innovative investigators as the recipients of this year’s Paul Marks Prize for Cancer Research.

… Monday, November 8, 2021 Memorial Sloan Kettering Cancer Center (MSK) is proud to announce three innovative investigators as the recipients of this year’s  Paul Marks Prize for Cancer Research . The prize, named in honor of MSK’s past President Emeritus, the late Paul Marks, MD, recognizes a new generation

Physician-scientist Michael S. Glickman specializes in the treatment and study of infectious diseases.

… Wednesday, October 1, 2008 Summary Physician-scientist Michael S. Glickman specializes in the treatment and study of infectious diseases. Physician-scientist Michael S. Glickman specializes in the treatment and study of infectious diseases. In the clinic he cares for cancer patients with a wide variety

MSK-ACCESS, a blood test that can detect mutations in 129 genes related to cancer, has already helped guide the treatment of more than 2,800 patients at MSK.

… Thursday, July 1, 2021 One of the most exciting recent developments in cancer care has been the increased use of liquid biopsies to analyze tumors. These tests, which are noninvasive and only require blood for testing, enable doctors to determine the genetic mutations driving the growth of a patient’

Tumor genomics and clinicopathologic features better predict recurrent lung adenocarcinoma (LUAD) following primary resection compared with the TNM classification system, according to a recent study from MSK.

… Monday, July 11, 2022 Tumor genomics and clinicopathologic features better predict recurrent lung adenocarcinoma (LUAD) following primary resection compared with the TNM classification system, according to a recent study from Memorial Sloan Kettering Cancer Center (MSK) published in JAMA Surgery .  (

Research led by investigators at Memorial Sloan Kettering Cancer Center has shown that therapeutic cloning, also known as somatic-cell nuclear transfer (SCNT), can be used to treat Parkinson's disease in mice.

… Sunday, March 23, 2008 Research led by investigators at Memorial Sloan Kettering Cancer Center (MSKCC) has shown that therapeutic cloning, also known as somatic-cell nuclear transfer (SCNT), can be used to treat Parkinson’s disease in mice. The study’s results are published in the March 23 online edition

Dr. Offodile will serve as MSK’s “futurist,” leading strategy efforts and care transformation initiatives at MSK by continuing to develop the core infrastructure, management systems, and processes for enterprise strategy and business development.

… Monday, April 24, 2023 Memorial Sloan Kettering Cancer Center (MSK) today announced that Anaeze Offodile II, MD, MPH , will join the institution as Chief Strategy Officer (CSO) on May 1. Dr. Offodile — a double board-certified physician with clinical expertise in oncologic reconstruction, a health services

Pexidartinib is the first drug approved specifically to treat tenosynovial giant cell tumor.

… Monday, August 5, 2019 Summary Pexidartinib is the first drug approved specifically to treat the rare joint tumor tenosynovial giant cell tumor, which is also known as pigmented villonodular synovitis. On August 2, the US Food and Drug Administration announced that it had approved pexidartinib (Turalio

Learn from MSK experts about how to quit smoking if you have cancer. It starts with having honest conversations about smoking and nicotine addiction.

… Friday, April 5, 2019 Summary Four MSK experts share strategies specifically for people with cancer to help them quit smoking. Most people know that smoking is the leading cause of cancer. But there is much less awareness among people with cancer — and their doctors — that smoking is associated with

Memorial Sloan Kettering Cancer Center has filed an application with the New York State Department of Health to open a freestanding outpatient facility in Harrison, New York. If approved, the new 114,000-square-foot treatment facility will offer area residents the most advanced cancer care services, closer to home.

… Monday, January 31, 2011 Memorial Sloan Kettering Cancer Center has filed an application with the New York State Department of Health to open a freestanding outpatient facility in Harrison, New York. If approved, the new 114,000-square-foot treatment facility will offer area residents the most advanced